← Back to all trials
Not Yet Recruiting
NCT07665749
Efficacy and Tolerability of Treatment With Alfalitic Plus Serenoa Repens Compared to Alfalitic Plus Antimuscarinic for Moderate-severe Lower Urinary Tract Symptoms
Conditions: Benign Prostate Hypertrophy(BPH)
Sex: Male
Ages: 40 Years – 80 Years
Healthy volunteers: No
Enrollment: 50
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Summary
The study aims to investigate, through the International Prostatic Symptoms Score (IPSS) questionnaire, the non-inferiority of the therapy with the alpha-blockers+Serenoa repens combination compared to the alpha-blockers+antimuscarinic combination on storage lower urinary tract syndrome (LUTS) in patients with moderate-severe symptomatic benign prostatic hyperplasia (BPH).
Eligibility Criteria
Inclusion Criteria:
* Age 40-80 inclusive
* Male
* With moderate-to-severe LUTS from BPH according to IPSS score
* Placed on AB+Serenoa repens or AB+antimuscarinics for 6 months
Exclusion Criteria:
* Prostate or bladder cancer
* History of neurogenic bladder
* Urinary tract abnormalities (including urethral strictures)
Source: ClinicalTrials.gov (NCT07665749). StuddyBuddy aggregates publicly available trial information.
